川崎病休克综合征的诊治进展

Abstract
Figure/Table
References (35)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract Kawasaki disease (KD) is a common vasculitis in children with fever as the main manifestation.Kawasaki disease shock syndrome (KDSS) is a rare form of KD,characterized by sustained systolic blood pressure lower than 20%or more of normal low systolic blood pressure in children of the same age,or accompanied by a clinical sign of poor tissue perfusion.Because its early symptoms are not typical,it is often confused with septic shock in clinical practice,which affects the diagnosis and treatment of children.Therefore,early recognition of the disease is particularly important for pediatric clinicians.This article summarizes KDSS from its pathogenesis,clinical manifestations,laboratory indicators,treatment and prognosis,so as to facilitate early treatment and improve the prognosis of children.

Key words： Kawasaki disease Kawasaki disease shock syndrome Diagnosis Treatment

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Ye
	XIAO Dong-qiong

Cite this article:

CHEN Ye,XIAO Dong-qiong. Progress in diagnosis and treatment of Kawasaki disease shock syndrome[J]. 中国当代医药, 2021, 28(7): 20-23.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I7/20

[1]	Sundel RP.Kawasaki disease[J].Rheum Dis Clin North Am，2015，41（1）：63-73.
[2]	Kanegaye JT，Wilder MS，Molkara D，et al.Recognition of a Kawasaki disease shock syndrome[J].Pediatrics，2009，123（5）：e783-e789.
[3]	Seo YM，Kang HM，Lee SC，et al.Clinical implications in laboratory parameter values in acute Kawasaki disease for early diagnosis and proper treatment[J].Korean J Pediatr，2018，61（5）：160-166.
[4]	Pineton de Chambrun M，Luyt CE，Beloncle F，et al.The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission[J].Crit Care Med，2017，45（7）：1216-1223.
[5]	Park S，Eun LY，Kim JH.Relationship between serum sodium level and coronary artery abnormality in Kawasaki disease[J].Korean J Pediatr，2017，60（2）：38-44.
[6]	Cakan M，Gemici H，Aktay-Ayaz N，et al.Kawasaki disease shock syndrome：a rare and severe complication of Kawasaki disease[J].Turk J Pediatr，2016，58（4）：415-418.
[7]	Liang YC，Cha ng CH，Lin MT，et al.Shock and unresponsiveness to repeated courses of intravenous immunoglobulin in Kawasaki disease：a nationwide database study[J].Pediatr Res，2020，87（5）：961-966.
[8]	Dionne A，Dahdah N.Myocarditis and Kawasaki disease[J].Int J Rheum Dis，2018，21（1）：45-49.
[9]	Parthasarathy P，Agarwal A，Chawla K，et al.Upcoming biomarkers for the diagnosis of Kawasaki disease：A review[J].Clin Biochem，2015，48（16-17）：1188-1194.
[10]	Lin KH，Chang SS，Yu CW，et al.Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease：a systematic review and meta-analysis[J].BMJ Open，2015，5（4）：e6703.
[11]	Xie T，Wang Y，Fu S，et al.Predictors for intravenous immunoglobulin resistance and coronary artery lesions in Kawasaki disease[J].Pediatr Rheumatol Online J，2017，15（1）：17.
[12]	Wakita D，Kurashima Y，Crother TR，et al.Role of Interleukin-1 Signaling in a Mouse Model of Kawasaki Disease-Associated Abdominal Aortic Aneurysm[J].Arterioscler Thromb Vasc Biol，2016，36（5）：886-897.
[13]	Li Y，Zheng Q，Zou L，et al.Kawasaki disease shock syndrome：clinical characteristics and possible use of IL-6，IL-10 and IFN-γ as biomarkers for early recognition[J].Pediatr Rheumatol Online J，2019，17（1）：1.
[14]	Lin MT，Fu CM，Huang SK，et al.Population-based study of Kawasaki disease shock syndrome in Taiwan[J].Pediatr Infect Dis J，2013，32（12）：1384-1386.
[15]	Chen PS，Chi H，Huang FY，et al.Clinical manifestations of Kawasaki disease shock syndrome：a case-control study[J].J Microbiol Immunol Infect，2015，48（1）：43-50.
[16]	李薇玢，刘琮，谭卫群，等.川崎病休克综合征的实验室指标及超声特点分析[J].中华实用儿科临床杂志，2019，34（19）：1476-1479.
[17]	Lee NH，Choi HJ，Kim YH.Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children[J].Korean J Pediatr，2017，60（4）：112-117.
[18]	Patel RM，Shulman ST.Kawasaki disease：a comprehensive review of treatment options[J].J Clin Pharm Ther，2015，40（6）：620-625.
[19]	Ha KS，Lee J，Jang GY，et al.Value of neutrophil-lymphocyte ratio in predicting outcomes in Kawasaki disease[J].Am J Cardiol，2015，116（2）：301-306.
[20]	Qiu H，Li C，He Y，et al.Association between left ventricular ejection fraction and Kawasaki disease shock syndrome[J].Cardiol Young，2019，29（2）：178-184.
[21]	Dietz SM，Tacke CE，Kuipers IM，et al.Cardiovascular imaging in children and adults following Kawasaki disease[J].Insights Imaging，2015，6（6）：697-705.
[22]	Taddio A，Rossi ED，Monasta L，et al.Describing Kawasaki shock syndrome：results from a retrospective study and literature review[J].Clin Rheumatol，2017，36（1）：223-228.
[29]	Newburger JW.Kawasaki disease：Medical therapies[J].Congenit Heart Dis，2017，12（5）：641-643.
[34]	Zhang H，Xie L，Xiao T.Extracorporeal Membrane Oxygenation Support for Cardiac Dysfunction Due to Kawasaki Disease Shock Syndrome[J].Front Pediatr，2019，7：221.
[23]	Bayers S，Shulman ST，Paller AS.Kawasaki disease：part Ⅱ.Complications and treatment[J].J Am Acad Dermatol，2013，69（4）：513.e1-8；quiz 521-522.
[24]	Ikeda K，Mizoro Y，Ameku T，et al.Transcriptional Analysis of Intravenous Immunoglobulin Resistance in Kawasaki Disease Using an Induced Pluripotent Stem Cell Disease Model[J].Circ J，2016，81（1）：110-118.
[25]	Agarwal S，Agrawal DK.Kawasaki disease：etiopathogenesis and novel treatment strategies[J].Expert Rev Clin Immunol，2017，13（3）：247-258.
[26]	Saneeymehri S，Baker K，So TY.Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease[J].J Pediatr Pharmacol Ther，2015，20（3）：163-177.
[27]	McCrindle BW，Rowley AH，Newburger JW，et al.Diagnosis，Treatment，and Long-Term Management of Kawasaki Disease：A Scientific Statement for Health Professionals From the American Heart Association[J].Circulation，2017，135（17）：e927-e999.
[28]	Hamada H，Suzuki H，Onouchi Y，et al.Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of nonresponse to intravenous immunoglobulin （KAICA）：a randomised controlled，open-label，blinded-endpoints，phase 3 trial[J].Lancet，2019，393（10176）：1128-1137.
[30]	Jang H，Kim KY，Kim DS.Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease[J].Yonsei Med J，2018，59（1）：113-118.
[31]	Choueiter NF，Olson AK，Shen DD，et al.Prospective openlabel trial of etanercept as adjunctive therapy for kawasaki disease[J].J Pediatr，2010，157（6）：960-966.
[32]	Xue LJ，Wu R，Du GL，et al.Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease：a Meta-analysis[J].Clin Rev Allergy Immunol，2017，52（3）：389-400.
[33]	Miao H，Cui Y，Wang F，et al.Continuous Hemofiltration Plus Plasma Exchange in Patient with Kawasaki Disease Shock Syndrome：A Case Report and Literature Review[J].Ann Clin Lab Sci，2019，49（6）：829-834.
[35]	Gamez-Gonzalez LB，Moribe-Quintero I，Cisneros-Castolo M，et al.Kawasaki disease shock syndrome：Unique and severe subtype of Kawasaki disease[J].Pediatrics International，2018，60（9）：781-790.